LOTIS-9 Trial of Zynlonta

ADC Therapeutics Halts LOTIS-9 Trial of Zynlonta for DLBCL Patients

Discontinuation of LOTIS-9 Trial: Zynlonta in Unfit DLBCL Patients

SG Tylor

Source – ADC Therapeutics On July 20, 2023,  ADC Therapeutics announced its decision to discontinue the Phase II LOTIS-9 clinical ...